XERIANT, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that XERIANT, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Jun 30, 2018 | $79.7K | Sep 25, 2019 |
| FY2019 | Jun 30, 2017 | $630.0K | Sep 25, 2019 |
| FY2017 | Jun 30, 2016 | $2.29M | Nov 21, 2018 |
| FY2016 | Jun 30, 2015 | $2.76M | Mar 3, 2017 |
| FY2015 | Jun 30, 2014 | $2.26M | Aug 25, 2016 |
| FY2014 | Jun 30, 2013 | $1.72M | Oct 14, 2014 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Jun 30, 2018 | $57.5K | Sep 25, 2019 |
| FY2019 | Jun 30, 2017 | $436.6K | Sep 25, 2019 |
| FY2017 | Jun 30, 2016 | $753.6K | Nov 21, 2018 |
| FY2016 | Jun 30, 2015 | $960.0K | Mar 3, 2017 |
| FY2015 | Jun 30, 2014 | $899.9K | Aug 25, 2016 |
| FY2014 | Jun 30, 2013 | $747.1K | Oct 14, 2014 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($1.65M) | Oct 2, 2025 |
| FY2025 | Jun 30, 2024 | ($3.10M) | Oct 2, 2025 |
| FY2024 | Jun 30, 2023 | ($7.10M) | Oct 8, 2024 |
| FY2023 | Jun 30, 2022 | ($13.30M) | Oct 16, 2023 |
| FY2022 | Dec 31, 2021 | ($5.53M) | Feb 15, 2022 |
| FY2022 | Sep 30, 2021 | ($4.45M) | Feb 15, 2022 |
| FY2022 | Jun 30, 2021 | ($2.70M) | Oct 13, 2022 |
| FY2022 | Dec 31, 2020 | ($1.19M) | Feb 15, 2022 |
| FY2021 | Jun 30, 2020 | ($699.6K) | Oct 15, 2021 |
| FY2020 | Jun 30, 2019 | ($84.8K) | Sep 30, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($1.37M) | Oct 2, 2025 |
| FY2025 | Jun 30, 2024 | ($1.91M) | Oct 2, 2025 |
| FY2024 | Jun 30, 2023 | ($2.05M) | Oct 8, 2024 |
| FY2023 | Jun 30, 2022 | ($11.01M) | Oct 16, 2023 |
| FY2022 | Dec 31, 2021 | ($4.26M) | Feb 15, 2022 |
| FY2022 | Jun 30, 2021 | ($2.20M) | Oct 13, 2022 |
| FY2022 | Dec 31, 2020 | ($1.12M) | Feb 15, 2022 |
| FY2021 | Jun 30, 2020 | ($362.7K) | Oct 15, 2021 |
| FY2020 | Jun 30, 2019 | ($84.4K) | Sep 30, 2020 |
| FY2019 | Jun 30, 2018 | ($322.8K) | Mar 31, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $69.3K | Oct 2, 2025 |
| FY2025 | Jun 30, 2024 | $196.4K | Oct 2, 2025 |
| FY2024 | Jun 30, 2023 | $0 | Oct 8, 2024 |
| FY2023 | Jun 30, 2022 | $5.27M | Oct 16, 2023 |
| FY2022 | Dec 31, 2021 | $2.86M | Feb 15, 2022 |
| FY2022 | Jun 30, 2021 | $373.1K | Oct 13, 2022 |
| FY2022 | Dec 31, 2020 | $0 | Feb 15, 2022 |
| FY2021 | Jun 30, 2020 | $6.4K | Oct 15, 2021 |
| FY2020 | Jun 30, 2019 | $8.4K | Sep 30, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Jun 30, 2018 | $3.7K | Sep 25, 2019 |
| FY2019 | Jun 30, 2017 | $112.8K | Sep 25, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($1.29M) | Oct 2, 2025 |
| FY2025 | Jun 30, 2024 | ($1.43M) | Oct 2, 2025 |
| FY2024 | Jun 30, 2023 | ($1.17M) | Oct 8, 2024 |
| FY2023 | Jun 30, 2022 | ($6.93M) | Oct 16, 2023 |
| FY2022 | Dec 31, 2021 | ($6.01M) | Feb 15, 2022 |
| FY2022 | Jun 30, 2021 | ($1.01M) | Oct 13, 2022 |
| FY2022 | Dec 31, 2020 | ($162.6K) | Feb 15, 2022 |
| FY2021 | Jun 30, 2020 | ($349.6K) | Oct 15, 2021 |
| FY2020 | Jun 30, 2019 | ($82.2K) | Sep 30, 2020 |
| FY2019 | Jun 30, 2018 | ($52.3K) | Mar 31, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.8K | Oct 2, 2025 |
| FY2025 | Jun 30, 2024 | $0 | Oct 2, 2025 |
| FY2024 | Jun 30, 2023 | $2.6K | Oct 8, 2024 |
| FY2023 | Jun 30, 2022 | $20.0K | Oct 16, 2023 |
| FY2022 | Dec 31, 2021 | $5.0K | Feb 15, 2022 |
| FY2022 | Jun 30, 2021 | $0 | Oct 13, 2022 |
| FY2022 | Dec 31, 2020 | $0 | Feb 15, 2022 |
| FY2017 | Jun 30, 2016 | $2.3K | Nov 21, 2018 |
| FY2016 | Jun 30, 2015 | $3.6K | Mar 3, 2017 |
| FY2014 | Jun 30, 2014 | $8.4K | Oct 14, 2014 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $68.2K | Oct 2, 2025 |
| FY2025 | Jun 30, 2024 | $713.0K | Oct 2, 2025 |
| FY2024 | Jun 30, 2023 | $167.1K | Oct 8, 2024 |
| FY2023 | Jun 30, 2022 | $1.27M | Oct 16, 2023 |
| FY2022 | Dec 31, 2021 | $2.28M | Feb 15, 2022 |
| FY2022 | Jun 30, 2021 | $1.15M | Oct 13, 2022 |
| FY2021 | Jun 30, 2020 | $258.9K | Oct 15, 2021 |
| FY2020 | Jun 30, 2019 | $3.0K | Sep 30, 2020 |
| FY2019 | Jun 30, 2018 | $23.9K | Mar 31, 2020 |
| FY2019 | Jun 30, 2017 | $30.5K | Sep 25, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $8.77M | Oct 2, 2025 |
| FY2025 | Jun 30, 2024 | $9.33M | Oct 2, 2025 |
| FY2024 | Jun 30, 2023 | $6.79M | Oct 8, 2024 |
| FY2023 | Jun 30, 2022 | $4.23M | Oct 16, 2023 |
| FY2022 | Dec 31, 2021 | $938.1K | Feb 15, 2022 |
| FY2022 | Jun 30, 2021 | $440.2K | Oct 13, 2022 |
| FY2021 | Jun 30, 2020 | $290.1K | Oct 15, 2021 |
| FY2020 | Jun 30, 2019 | $36.9K | Sep 30, 2020 |
| FY2019 | Jun 30, 2018 | $4.09M | Mar 31, 2020 |
| FY2019 | Jun 30, 2017 | $3.26M | Sep 25, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($5.82M) | Oct 2, 2025 |
| FY2025 | Jun 30, 2024 | ($5.75M) | Oct 2, 2025 |
| FY2024 | Jun 30, 2023 | ($3.79M) | Oct 8, 2024 |
| FY2023 | Jun 30, 2022 | ($164.1K) | Oct 16, 2023 |
| FY2022 | Dec 31, 2021 | $1.34M | Feb 15, 2022 |
| FY2022 | Sep 30, 2021 | $122.7K | Feb 15, 2022 |
| FY2022 | Jun 30, 2021 | $922.0K | Oct 13, 2022 |
| FY2021 | Jun 30, 2020 | ($31.2K) | Oct 15, 2021 |
| FY2021 | Jun 30, 2019 | ($33.8K) | Oct 15, 2021 |
| FY2020 | Aug 6, 2018 | $0 | Sep 30, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($28.34M) | Oct 2, 2025 |
| FY2025 | Jun 30, 2024 | ($26.71M) | Oct 2, 2025 |
| FY2024 | Jun 30, 2023 | ($23.64M) | Oct 8, 2024 |
| FY2023 | Jun 30, 2022 | ($16.57M) | Oct 16, 2023 |
| FY2022 | Dec 31, 2021 | ($10.03M) | Feb 15, 2022 |
| FY2022 | Jun 30, 2021 | ($3.27M) | Oct 13, 2022 |
| FY2021 | Jun 30, 2020 | ($784.3K) | Oct 15, 2021 |
| FY2020 | Jun 30, 2019 | ($84.8K) | Sep 30, 2020 |
| FY2019 | Jun 30, 2018 | ($6.12M) | Mar 31, 2020 |
| FY2019 | Jun 30, 2017 | ($5.28M) | Sep 25, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $2.11M | Feb 15, 2022 |
| FY2022 | Jun 30, 2021 | $962.5K | Feb 15, 2022 |
| FY2022 | Dec 31, 2020 | $19.6K | Feb 15, 2022 |
| FY2022 | Jun 30, 2020 | $38.9K | Feb 15, 2022 |
| FY2021 | Jun 30, 2019 | $3.0K | Oct 15, 2021 |
| FY2020 | Aug 6, 2018 | $0 | Sep 30, 2020 |
| FY2019 | Jun 30, 2017 | $4.5K | Sep 25, 2019 |
| FY2017 | Jun 30, 2016 | $11.1K | Nov 21, 2018 |
| FY2017 | Jun 30, 2015 | $362.7K | Nov 21, 2018 |
| FY2016 | Jun 30, 2014 | $33.4K | Mar 3, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Jun 30, 2022 | 0 | Oct 13, 2022 |
| FY2022 | Jun 30, 2021 | 0 | Oct 13, 2022 |
| FY2019 | Jun 30, 2018 | 0 | Sep 25, 2019 |
| FY2019 | Jun 30, 2017 | 0 | Sep 25, 2019 |
| FY2017 | Jun 30, 2016 | 0 | Nov 21, 2018 |
| FY2016 | Jun 30, 2015 | 0 | Mar 3, 2017 |
| FY2015 | Jun 30, 2014 | 0 | Aug 25, 2016 |
| FY2014 | Jun 30, 2013 | 0 | Oct 14, 2014 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Oct 2, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Oct 2, 2025 |
| FY2022 | Jun 30, 2022 | 0 | Oct 13, 2022 |
| FY2022 | Jun 30, 2021 | 0 | Oct 13, 2022 |
| FY2019 | Jun 30, 2018 | 0 | Sep 25, 2019 |
| FY2019 | Jun 30, 2017 | 0 | Sep 25, 2019 |
| FY2017 | Jun 30, 2016 | 0 | Nov 21, 2018 |
| FY2016 | Jun 30, 2015 | 0 | Mar 3, 2017 |
| FY2015 | Jun 30, 2014 | 0 | Aug 25, 2016 |
| FY2014 | Jun 30, 2013 | 0 | Oct 14, 2014 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 695.75M | Oct 2, 2025 |
| FY2025 | Jun 30, 2024 | 524.85M | Oct 2, 2025 |
| FY2024 | Jun 30, 2023 | 389.43M | Oct 8, 2024 |
| FY2023 | Jun 30, 2022 | 365.24M | Oct 16, 2023 |
| FY2022 | Dec 31, 2021 | 292.82M | Feb 15, 2022 |
| FY2022 | Jun 30, 2021 | 292.82M | Oct 13, 2022 |
| FY2021 | Jun 30, 2020 | 69.58M | Oct 15, 2021 |
| FY2020 | Jun 30, 2019 | 0 | Sep 30, 2020 |
| FY2019 | Jun 30, 2018 | 69.58M | Mar 31, 2020 |
| FY2019 | Jun 30, 2017 | 69.58M | Sep 25, 2019 |